Stratec (SBS) Aktievy
Stratec SE, tillsammans med sina dotterbolag, utvecklar och tillverkar automations- och instrumentlösningar inom områdena in vitro-diagnostik och biovetenskap i Tyskland, EU och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 4/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 2/6 |
SBS Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Stratec SE Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | €17.60 |
| 52 veckors högsta | €33.10 |
| 52 veckors lägsta | €16.36 |
| Beta | 0.80 |
| 1 månads förändring | -0.90% |
| 3 månaders förändring | -21.25% |
| 1 års förändring | -28.02% |
| 3 års förändring | -72.11% |
| 5 års förändring | -84.56% |
| Förändring sedan börsintroduktionen | 238.27% |
Senaste nyheter och uppdateringar
SBS: Rebased Fair Value And 2025 Margin Guidance Will Define Upside Potential
The analyst price target for Stratec has been cut from about €44.96 to €34.00, as analysts factor in updated fair value, discount rate, growth, margin, and P/E assumptions following recent target revisions from major banks. Analyst Commentary Recent research suggests that while headline price targets for Stratec have come down, some bullish analysts still see potential upside at current levels.
SBS: Future Upside Will Rely On Reset Margins And Higher P/E
Narrative Update on Stratec The updated analyst price target for Stratec is €28.46, reflecting recent target cuts of up to €12 from prior Street research as analysts factor in a slightly higher discount rate, modestly adjusted profit margin assumptions, and a higher future P/E multiple. Analyst Commentary Recent research commentary on Stratec has focused on recalibrating price targets while keeping an eye on execution risk and the valuation investors are being asked to pay.SBS: Future Upside Will Depend On Repriced Earnings Power And Margins
Analysts have trimmed their average price target for Stratec by around €2.40, with recent cuts to €34 helping to explain a slightly lower fair value estimate and modestly softer assumptions for growth, margins and future P/E. Analyst Commentary Recent research revisions on Stratec point to a reset in expectations, with lower price targets feeding into updated views on valuation, execution risk and growth assumptions.Recent updates
SBS: Rebased Fair Value And 2025 Margin Guidance Will Define Upside Potential
The analyst price target for Stratec has been cut from about €44.96 to €34.00, as analysts factor in updated fair value, discount rate, growth, margin, and P/E assumptions following recent target revisions from major banks. Analyst Commentary Recent research suggests that while headline price targets for Stratec have come down, some bullish analysts still see potential upside at current levels.SBS: Future Upside Will Rely On Reset Margins And Higher P/E
Narrative Update on Stratec The updated analyst price target for Stratec is €28.46, reflecting recent target cuts of up to €12 from prior Street research as analysts factor in a slightly higher discount rate, modestly adjusted profit margin assumptions, and a higher future P/E multiple. Analyst Commentary Recent research commentary on Stratec has focused on recalibrating price targets while keeping an eye on execution risk and the valuation investors are being asked to pay.SBS: Future Upside Will Depend On Repriced Earnings Power And Margins
Analysts have trimmed their average price target for Stratec by around €2.40, with recent cuts to €34 helping to explain a slightly lower fair value estimate and modestly softer assumptions for growth, margins and future P/E. Analyst Commentary Recent research revisions on Stratec point to a reset in expectations, with lower price targets feeding into updated views on valuation, execution risk and growth assumptions.
SBS: Higher Discount Rate And Index Removal Will Still Allow Future Upside
Narrative Update on Stratec The analyst price target for Stratec has been reduced by €1, as analysts reflect slightly adjusted assumptions around discount rates, revenue growth and profit margins in their updated models. Analyst Commentary Bearish analysts trimming their price targets, including the recent €1 reduction, are signaling a more cautious stance on Stratec.SBS: Higher Discount Rate Will Still Allow Future Upside Potential
Analysts have reduced their price target on Stratec by €1 to €26, reflecting updated assumptions regarding the company’s discount rate, revenue growth, profit margin and future P/E profile. Analyst Commentary Bearish analysts cutting the price target to €26 are signaling a more cautious stance on Stratec’s risk and reward trade off at current levels.SBS: Future Upside Will Rely On Earnings Power And Cost Controls
Narrative update on Stratec Analysts have trimmed their 12 month price target on Stratec by about €1, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Recent research updates on Stratec point to a small pullback in published price targets, with a reduction of about €1 in the latest move and a prior cut from €30 to €27.SBS: Future Margin Recovery Will Rely On Efficiency Gains And Cost Controls
Analysts have trimmed their price target on Stratec, with the average moving slightly lower in line with a recent cut from €30 to €27, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Recent research points to a more cautious stance on Stratec, with the reduced €27 price target reflecting updated views on what analysts see as fair value, the applied discount rate, revenue growth assumptions, margin profile and future P/E expectations.Returns On Capital Signal Tricky Times Ahead For Stratec (ETR:SBS)
Jan 10
SBS: Index Exit And 2025 Margin Guidance Will Define Upside Potential
Analysts have trimmed their fair value estimate for Stratec from about €51.00 to roughly €44.96. This aligns with a recent reduction in the Street price target to €27 from €30 as they factor in updated assumptions on discount rates, revenue growth, profit margins, and future P/E multiples.SBS: Margin Recovery Outlook Will Support Upside Despite Reduced Price Objective
Analysts have trimmed their price target on Stratec to EUR 27.00 from EUR 30.00, reflecting slightly more cautious assumptions on long term growth, a higher discount rate, and a modestly lower future P E multiple, despite marginally improved margin expectations. Analyst Commentary Bearish analysts have highlighted that the reduction in the price target to EUR 27.00 signals a more guarded stance on Stratec's medium to long term prospects, even as the rating on the shares remains unchanged at Hold.SBS: Future Margin Gains Will Emerge As Cost Controls Take Hold
Analysts have modestly reduced their price target on Stratec, trimming it by EUR 3 to EUR 27. This reflects slightly lower long term return expectations while maintaining a cautious stance on the shares.Stratec (ETR:SBS) Takes On Some Risk With Its Use Of Debt
Nov 29SBS: Margins Will Improve With Cost Management And Leadership Changes
The analyst price target for Stratec has been revised downward from €30 to €27. Analysts cited a slightly higher discount rate and modest changes in growth and profitability expectations as key drivers behind the adjustment.Stratec SE (ETR:SBS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 11Investors Give Stratec SE (ETR:SBS) Shares A 35% Hiding
Nov 07SBS: Future Leadership Will Drive Healthcare Diagnostics Forward Amidst Margin Pressures
Analysts have revised their price target for Stratec downward from €36.58 to €33.30, citing expectations of slower revenue growth and a slight decrease in profit margins. What's in the News Tanja Bücherl will join STRATEC SE's Board of Management as Chief Financial Officer effective November 1, 2025.Getting In Cheap On Stratec SE (ETR:SBS) Might Be Difficult
Sep 23Automation And Digitalization Will Transform Healthcare Diagnostics
Stratec’s consensus price target has been revised downward, primarily reflecting lowered forecasts for both revenue growth and net profit margin, resulting in a new fair value of €37.32. What's in the News Stratec increased its dividend to €0.60 per share for 2024 (previously €0.55), totaling €7.3 million to be distributed.An Intrinsic Calculation For Stratec SE (ETR:SBS) Suggests It's 34% Undervalued
Jun 17Why We're Not Concerned About Stratec SE's (ETR:SBS) Share Price
Apr 25
Efficiency Measures And Acquisitions Like Natech Will Boost Future Market Presence
Efficiency measures and cost discipline initiatives could enhance net margins as market conditions stabilize.An Intrinsic Calculation For Stratec SE (ETR:SBS) Suggests It's 42% Undervalued
Jan 18With A 25% Price Drop For Stratec SE (ETR:SBS) You'll Still Get What You Pay For
Nov 09Returns At Stratec (ETR:SBS) Appear To Be Weighed Down
Oct 26Here's Why It's Unlikely That Stratec SE's (ETR:SBS) CEO Will See A Pay Rise This Year
May 11Stratec's (ETR:SBS) Dividend Will Be Reduced To €0.55
Apr 11Stratec SE Just Missed EPS By 24%: Here's What Analysts Think Will Happen Next
Apr 01Stratec (ETR:SBS) Has Announced That Its Dividend Will Be Reduced To €0.55
Mar 28Is There An Opportunity With Stratec SE's (ETR:SBS) 36% Undervaluation?
Dec 21Slowing Rates Of Return At Stratec (ETR:SBS) Leave Little Room For Excitement
Nov 03We Think Stratec (ETR:SBS) Is Taking Some Risk With Its Debt
Oct 19Return Trends At Stratec (ETR:SBS) Aren't Appealing
Jul 12Stratec SE (ETR:SBS) Shares Could Be 43% Below Their Intrinsic Value Estimate
Jun 27Is Stratec (ETR:SBS) Using Too Much Debt?
May 25Stratec's (ETR:SBS) Upcoming Dividend Will Be Larger Than Last Year's
Apr 02Aktieägarnas avkastning
| SBS | DE Medical Equipment | DE Marknad | |
|---|---|---|---|
| 7D | -4.3% | -1.3% | 0.06% |
| 1Y | -28.0% | -28.7% | 1.0% |
Avkastning vs industri: SBS matchade German Medical Equipment branschen som gav -28.7 % under det senaste året.
Avkastning vs Marknaden: SBS presterade sämre än German marknaden som gav 1 % under det senaste året.
Prisvolatilitet
| SBS volatility | |
|---|---|
| SBS Average Weekly Movement | 6.3% |
| Medical Equipment Industry Average Movement | 5.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stabil aktiekurs: SBS har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för German.
Volatilitet över tid: SBS s veckovolatilitet ( 6% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1979 | 1,420 | Marcus Wolfinger | www.stratec.com |
Stratec SE, tillsammans med sina dotterbolag, utvecklar och tillverkar automations- och instrumentlösningar inom in vitro-diagnostik och biovetenskap i Tyskland, EU och internationellt. Företaget konstruerar och tillverkar automatiserade analyssystem för kunder inom klinisk diagnostik och bioteknik samt erbjuder komplexa förbrukningsvaror för diagnostik och medicinska tillämpningar. Företaget var tidigare känt som STRATEC Biomedical AG och bytte namn till Stratec SE i december 2018.
Stratec SE Sammanfattning av grunderna
| SBS grundläggande statistik | |
|---|---|
| Börsvärde | €213.94m |
| Vinst(TTM) | -€242.00k |
| Intäkter(TTM) | €250.86m |
0.9x
P/S-förhållande-884.1x
P/E-förhållandeÄr SBS övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| SBS resultaträkning (TTM) | |
|---|---|
| Intäkter | €250.86m |
| Kostnad för intäkter | €186.64m |
| Bruttovinst | €64.22m |
| Övriga kostnader | €64.46m |
| Intäkter | -€242.00k |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
May 11, 2026
| Vinst per aktie (EPS) | -0.02 |
| Bruttomarginal | 25.60% |
| Nettovinstmarginal | -0.097% |
| Skuld/egenkapitalförhållande | 0% |
Hur har SBS utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
3.4%
Aktuell utdelningsavkastning47%
UtbetalningskvotGer SBS en tillförlitlig utdelning?
Se SBS utdelningshistorik och jämförelsetal| Stratec datum för utdelning | |
|---|---|
| Ex utdelningsdag | Jun 24 2026 |
| Utbetalningsdag för utdelning | Jun 26 2026 |
| Dagar till Ex-utdelning | 52 days |
| Dagar till utdelningsdag | 54 days |
Ger SBS en tillförlitlig utdelning?
Se SBS utdelningshistorik och jämförelsetalFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/02 19:01 |
| Aktiekurs vid dagens slut | 2026/04/30 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Stratec SE bevakas av 11 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Michael Heider | Berenberg |
| Jan Koch | Deutsche Bank |
| Jan Koch | Deutsche Bank |